Akston Launches Clinical Trial for Next-Generation Canine Cancer Immunotherapy
Akston has initiated a Purdue University clinical trial of its Ambifect® immuno-enhancing protein therapy targeting PD-L1 in dogs with solid tumors — marking the company’s first in-clinic study of its novel Fc-fusion platform.